ES2312184T3
(es)
|
1997-03-21 |
2009-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
|
CN101469329B
(zh)
|
1998-11-27 |
2012-10-24 |
达尔文发现有限公司 |
增加骨矿化的组合物和方法
|
PT1491208E
(pt)
*
|
1999-10-04 |
2010-05-12 |
Novartis Vaccines & Diagnostic |
Composições farmacêuticas contendo polipéptido líquidas estabilizadas
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
DE60139944D1
(de)
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
US20140186361A1
(en)
|
2012-09-07 |
2014-07-03 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Adalimumab
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
CN101653604A
(zh)
*
|
2001-05-30 |
2010-02-24 |
基因技术股份有限公司 |
抗ngf抗体用于治疗各种疾病
|
AU2006202688B2
(en)
*
|
2001-05-31 |
2009-01-22 |
Genentech, Inc. |
Stable liquid formulations of antibodies
|
GB0113179D0
(en)
*
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
US20080026068A1
(en)
*
|
2001-08-16 |
2008-01-31 |
Baxter Healthcare S.A. |
Pulmonary delivery of spherical insulin microparticles
|
PT1441589E
(pt)
*
|
2001-11-08 |
2012-08-13 |
Abbott Biotherapeutics Corp |
Formulação farmacêutica líquida estável de anticorpos igg
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
NZ537687A
(en)
*
|
2002-06-21 |
2008-04-30 |
Biogen Idec Inc |
Buffered formulations for concentrating antibodies and methods of use thereof
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
WO2004060343A1
(en)
*
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics |
Antibody-containing particles and compositions
|
SI1599222T1
(sl)
*
|
2003-01-08 |
2009-08-31 |
Novartis Vaccines & Diagnostic |
Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
JP4869064B2
(ja)
*
|
2003-04-04 |
2012-02-01 |
ジェネンテック, インコーポレイテッド |
高濃度抗体及びタンパク質製剤
|
GB2401040A
(en)
*
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EA015166B1
(ru)
|
2003-06-16 |
2011-06-30 |
Ю-Си-Би Мэньюфэкчуринг, Инк. |
Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
|
AU2004259398A1
(en)
*
|
2003-06-27 |
2005-02-03 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
DE10348550A1
(de)
*
|
2003-10-20 |
2005-06-16 |
Hexal Biotech Forschungsgmbh |
Stabile wässrige G-CSF-haltige Zusammensetzungen
|
SI1682184T1
(sl)
*
|
2003-11-04 |
2014-02-28 |
Lek Pharmaceuticals D.D. |
Stabilen farmacevtski sestavek, obsegajoč faktor za stimulacijo kolonije granulocitov
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
JPWO2005063291A1
(ja)
*
|
2003-12-25 |
2007-07-19 |
麒麟麦酒株式会社 |
抗体を含有する安定な水性医薬製剤
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
DE602005009954D1
(de)
*
|
2004-05-12 |
2008-11-06 |
Baxter Int |
Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
|
AU2005244840C1
(en)
*
|
2004-05-12 |
2012-05-10 |
Baxter Healthcare S.A. |
Microspheres comprising protein and showing injectability at high concentrations of said agent
|
EP1758558B1
(en)
*
|
2004-05-12 |
2013-10-16 |
Baxter International Inc. |
Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
|
US8728525B2
(en)
*
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
ZA200700947B
(en)
*
|
2004-07-23 |
2008-06-25 |
Genentech Inc |
Crystallization of antibodies or fragments thereof
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
US7655758B2
(en)
|
2004-08-17 |
2010-02-02 |
Regeneron Pharmaceuticals, Inc. |
Stable liquid IL-1 antagonist formulations
|
US7572893B2
(en)
*
|
2004-08-17 |
2009-08-11 |
Regeneron Pharmaceuticals, Inc. |
IL-1 antagonist formulations
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
PL1861116T3
(pl)
|
2005-03-25 |
2016-02-29 |
Regeneron Pharma |
Formulacje antagonistów VEGF
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
CN101222926B
(zh)
*
|
2005-04-15 |
2013-07-17 |
默沙东公司 |
用于治疗或预防癌症的方法和组合物
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
CA2607663C
(en)
|
2005-05-19 |
2014-08-12 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
EP3673919A1
(en)
|
2005-06-14 |
2020-07-01 |
Amgen Inc. |
Self-buffering protein formulations
|
EP3225233B1
(en)
*
|
2005-11-01 |
2019-08-14 |
Wyeth LLC |
Sodium chloride solution for drug reconstitution
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
EP1962907A2
(en)
*
|
2005-12-21 |
2008-09-03 |
Wyeth a Corporation of the State of Delaware |
Protein formulations with reduced viscosity and uses thereof
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
US20080071063A1
(en)
*
|
2006-02-03 |
2008-03-20 |
Medimmune, Inc. |
Protein Formulations
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP2021030A2
(en)
*
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
CN101478949A
(zh)
|
2006-06-16 |
2009-07-08 |
瑞泽恩制药公司 |
适合玻璃体内施用的vegf拮抗剂的制剂
|
MX2009001226A
(es)
|
2006-08-04 |
2009-03-20 |
Baxter Int |
Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
|
EP2094247B1
(en)
|
2006-10-20 |
2022-06-29 |
Amgen Inc. |
Stable polypeptide formulations
|
AU2007322265B2
(en)
*
|
2006-11-07 |
2013-06-20 |
Merck Sharp & Dohme Corp. |
Antagonists of PCSK9
|
US20100040610A1
(en)
*
|
2006-11-07 |
2010-02-18 |
Ayesha Sitlani |
Antagonists of pcsk9
|
US20090060906A1
(en)
*
|
2007-01-09 |
2009-03-05 |
Wyeth |
Anti-IL-13 antibody formulations and uses thereof
|
CA2681743A1
(en)
*
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
US8168760B2
(en)
|
2007-03-29 |
2012-05-01 |
Abbott Laboratories |
Crystalline anti-human IL-12 antibodies
|
RU2491094C2
(ru)
*
|
2007-03-30 |
2013-08-27 |
Медиммун, Ллк |
Препарат антитела
|
WO2008131129A2
(en)
*
|
2007-04-17 |
2008-10-30 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
CN101674805A
(zh)
|
2007-05-02 |
2010-03-17 |
诺沃-诺迪斯克保健股份有限公司 |
包括芳香族防腐剂和抗氧化剂的高浓度因子ⅶ多肽制剂
|
AU2008255016B2
(en)
*
|
2007-05-15 |
2013-05-09 |
Stryker Corporation |
Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
|
AU2008256411B2
(en)
*
|
2007-06-01 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Immunoglobulin purification
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
US8637021B2
(en)
*
|
2007-11-12 |
2014-01-28 |
Ares Trading S.A. |
Formulations for TACI-immunoglobulin fusion proteins
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
EP2244814B1
(en)
*
|
2007-12-28 |
2021-06-02 |
Takeda Pharmaceutical Company Limited |
Recombinant vwf formulations
|
US11197916B2
(en)
|
2007-12-28 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Lyophilized recombinant VWF formulations
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
EP2285412A1
(en)
*
|
2008-05-23 |
2011-02-23 |
Novo Nordisk Health Care AG |
Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
|
CN102083459A
(zh)
*
|
2008-05-23 |
2011-06-01 |
诺沃-诺迪斯克保健股份有限公司 |
包括含有peg化的gla-结构域的蛋白质的低粘度组合物
|
EP2297203A1
(en)
*
|
2008-06-30 |
2011-03-23 |
Novo Nordisk A/S |
Anti-human interleukin-20 antibodies
|
NZ592704A
(en)
|
2008-10-21 |
2013-02-22 |
Baxter Int |
Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
|
NZ592644A
(en)
*
|
2008-11-28 |
2013-09-27 |
Abbott Lab |
Stable antibody compositions and methods for stabilizing same
|
SI2373681T1
(sl)
|
2008-12-10 |
2017-05-31 |
Glaxosmithkline Llc Corporation Service Company |
Farmacevtski sestavki albiglutida
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
EP2403874A1
(en)
*
|
2009-03-06 |
2012-01-11 |
Genentech, Inc. |
Antibody formulation
|
NZ595694A
(en)
*
|
2009-05-04 |
2013-09-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
CN102482345A
(zh)
|
2009-05-13 |
2012-05-30 |
航道生物技术有限责任公司 |
针对流感病毒的中和分子
|
AU2010266338B2
(en)
|
2009-07-01 |
2013-11-14 |
Fresenius Medical Care Holdings, Inc. |
Drug delivery devices and related systems and methods
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
JP2013501058A
(ja)
*
|
2009-08-04 |
2013-01-10 |
ジェネンテック, インコーポレイテッド |
低減された粘性を有する濃縮ポリペプチド製剤
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
US8454956B2
(en)
*
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
EP2473528B1
(en)
|
2009-09-03 |
2014-12-03 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
DK2493922T3
(en)
|
2009-10-26 |
2017-04-24 |
Hoffmann La Roche |
Process for preparing a glycosylated immunoglobulin
|
MX344935B
(es)
*
|
2009-10-26 |
2017-01-11 |
Genentech Inc |
Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
|
EP3708190A1
(en)
*
|
2010-02-26 |
2020-09-16 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
NZ602685A
(en)
*
|
2010-03-01 |
2014-10-31 |
Cytodyn Inc |
Concentrated protein formulations and uses thereof
|
CA3101298A1
(en)
|
2010-03-01 |
2011-09-09 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
SI2550018T1
(sl)
|
2010-03-22 |
2019-05-31 |
F. Hoffmann-La Roche Ag |
Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
|
MX2012012743A
(es)
*
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
JP2013525491A
(ja)
|
2010-05-04 |
2013-06-20 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
心血管障害を治療または予防し心血管保護を提供する方法
|
BR112012028920B1
(pt)
|
2010-05-14 |
2021-03-23 |
Amgen Inc. |
Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
|
US20130136733A1
(en)
|
2010-05-28 |
2013-05-30 |
Novo Nordisk A/S |
Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
|
CN103108658B
(zh)
*
|
2010-07-02 |
2015-08-19 |
米迪缪尼有限公司 |
抗体制剂
|
CN103476793A
(zh)
|
2010-11-08 |
2013-12-25 |
基因技术公司 |
皮下施用的抗-il-6受体抗体
|
TWI603739B
(zh)
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗-TNFα抗體之液體調配物
|
EP2644698B1
(en)
|
2010-11-17 |
2018-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
PE20140372A1
(es)
|
2011-01-28 |
2014-03-24 |
Sanofi Sa |
Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9
|
CA2825524C
(en)
|
2011-01-31 |
2021-03-23 |
Fresenius Medical Care Holdings, Inc. |
Preventing over-delivery of drug
|
CN103442744B
(zh)
|
2011-02-08 |
2017-02-15 |
弗雷塞尼斯医疗保健控股公司 |
磁性传感器及相关系统和方法
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
SG193610A1
(en)
|
2011-03-25 |
2013-11-29 |
Amgen Inc |
Anti - sclerostin antibody crystals and formulations thereof
|
AU2012243126A1
(en)
*
|
2011-04-07 |
2013-10-17 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
SG193963A1
(en)
*
|
2011-04-07 |
2013-11-29 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
HUE039786T2
(hu)
|
2011-08-04 |
2019-02-28 |
Amgen Inc |
Csonthiány-defektusok kezelési módszere
|
MY182178A
(en)
|
2011-09-01 |
2021-01-18 |
Chugai Pharmaceutical Co Ltd |
Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
|
JP6158813B2
(ja)
|
2011-09-16 |
2017-07-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
プロタンパク質転換酵素サブチリシンケキシン−9(PCSK9)の阻害剤を投与することによってリポタンパク質(a)レベルを低下させる方法
|
SG11201401360XA
(en)
|
2011-10-25 |
2014-05-29 |
Onclave Therapeutics Ltd |
Antibody formulations and methods
|
KR101759694B1
(ko)
|
2011-10-28 |
2017-07-19 |
인테그리티 바이오, 아이엔씨. |
아미노산을 함유하는 단백질 제제
|
LT3091029T
(lt)
|
2011-10-31 |
2023-02-27 |
F. Hoffmann-La Roche Ag |
Anti-il13 antikūno kompozicijos
|
BR112014010542A2
(pt)
|
2011-11-02 |
2017-04-18 |
Halscion Inc |
métodos e composições para tratamento de ferimento
|
WO2013070692A1
(en)
|
2011-11-07 |
2013-05-16 |
Battelle Memorial Institute |
Processes for delivery of viscous drug therapies
|
PL2596796T3
(pl)
|
2011-11-24 |
2014-04-30 |
Quimera Ingenieria Biomedica S L |
Kompleks otrzymany z mieszanin kwasu hialuronowego lub jego soli z siarczanem chondroityny
|
ES2710916T3
(es)
|
2011-12-22 |
2019-04-29 |
I2 Pharmaceuticals Inc |
Proteínas de unión sustitutas
|
SG11201403718YA
(en)
|
2011-12-28 |
2014-07-30 |
Amgen Inc |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
EP2807190B1
(en)
|
2012-01-23 |
2018-12-26 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-ang2 antibodies
|
US9144646B2
(en)
|
2012-04-25 |
2015-09-29 |
Fresenius Medical Care Holdings, Inc. |
Vial spiking devices and related assemblies and methods
|
SG10201709555SA
(en)
|
2012-05-18 |
2017-12-28 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
CN104364264B
(zh)
|
2012-06-06 |
2018-07-24 |
硕腾服务有限责任公司 |
犬源化抗ngf抗体和其方法
|
NZ702342A
(en)
*
|
2012-06-21 |
2016-07-29 |
Ucb Pharma Sa |
Pharmaceutical formulation
|
AU2013285488B2
(en)
|
2012-07-05 |
2018-03-22 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
WO2014015133A1
(en)
|
2012-07-19 |
2014-01-23 |
National Cheng Kung University |
Treatment of osteoarthritis using il-20 antagonists
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
FR2994390B1
(fr)
*
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
FR2995214B1
(fr)
*
|
2012-09-10 |
2014-11-21 |
Adocia |
Solution a viscosite reduite de proteine a concentration elevee
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
EP2926834A4
(en)
*
|
2012-11-27 |
2016-04-20 |
Alteogen Inc |
COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED
|
EP2968434B1
(en)
|
2013-03-15 |
2017-06-28 |
Shire Viropharma Incorporated |
C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).
|
WO2014141149A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations with reduced viscosity
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
BR112015032960B1
(pt)
|
2013-07-04 |
2021-01-05 |
F. Hoffmann-La Roche Ag |
imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
|
CN107318267B
(zh)
|
2013-08-12 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
用于治疗补体相关的病症的组合物和方法
|
EP3043775B1
(en)
|
2013-09-11 |
2020-11-04 |
Eagle Biologics, Inc. |
Liquid protein formulations containing viscosity-lowering agents
|
RU2758952C1
(ru)
|
2013-09-27 |
2021-11-03 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
MX2016006226A
(es)
|
2013-11-12 |
2016-09-07 |
Sanofi Biotechnology |
Regimenes de dosificacion para uso con inhibidores de pcsk9.
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EA201692109A1
(ru)
|
2014-05-01 |
2017-03-31 |
Дженентек, Инк. |
Варианты антител к фактору d и их применение
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
US20160074515A1
(en)
*
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
PL3169353T3
(pl)
|
2014-07-16 |
2020-06-01 |
Sanofi Biotechnology |
SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
|
MA40354A
(fr)
|
2014-07-18 |
2017-05-24 |
Sanofi Sa |
Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
KR102497368B1
(ko)
|
2014-10-01 |
2023-02-10 |
이글 바이올로직스 인코포레이티드 |
점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
|
TW201628649A
(zh)
|
2014-10-09 |
2016-08-16 |
再生元醫藥公司 |
減少醫藥調配物中微可見顆粒之方法
|
WO2016059512A1
(en)
*
|
2014-10-18 |
2016-04-21 |
Pfizer Inc. |
Anti-il-7r antibody compositions
|
WO2016071376A2
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
CN107206080B
(zh)
|
2015-01-28 |
2022-07-08 |
辉瑞公司 |
稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
WO2017007835A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for nanoemulsion vaccine formulations
|
US20170007690A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for the stabilization of anthrax recombinant protective antigen
|
JP2018521129A
(ja)
*
|
2015-07-07 |
2018-08-02 |
ナノビオ コーポレイションNanobio Corporation |
タンパク質の安定化のための方法および組成物
|
PT3334747T
(pt)
|
2015-08-13 |
2023-12-12 |
Amgen Inc |
Formulação de gonadotrofina líquida estável
|
US10772956B2
(en)
|
2015-08-18 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
KR20180091918A
(ko)
|
2015-12-28 |
2018-08-16 |
추가이 세이야쿠 가부시키가이샤 |
Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
TW202402326A
(zh)
|
2016-04-28 |
2024-01-16 |
日商中外製藥股份有限公司 |
含抗體製劑
|
EP3254671B1
(en)
|
2016-06-10 |
2019-11-13 |
Octapharma AG |
High concentration immunoglobulin composition for pharmaceutical application
|
EP3493832A1
(en)
|
2016-08-05 |
2019-06-12 |
CSL Behring GmbH |
Pharmaceutical formulations of c1 esterase inhibitor
|
MY196321A
(en)
|
2016-08-16 |
2023-03-24 |
Regeneron Pharma |
Methods for Quantitating Individual Antibodies From a Mixture
|
MX2019002510A
(es)
|
2016-09-06 |
2019-06-24 |
Chugai Pharmaceutical Co Ltd |
Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
|
JP6884858B2
(ja)
|
2016-10-21 |
2021-06-09 |
アムジエン・インコーポレーテツド |
医薬製剤及びその製造方法
|
WO2018081203A1
(en)
|
2016-10-25 |
2018-05-03 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for chromatography data analysis
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
US11845798B2
(en)
|
2017-05-02 |
2023-12-19 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
SG11202001281WA
(en)
|
2017-08-22 |
2020-03-30 |
Biogen Ma Inc |
Pharmaceutical compositions containing anti-beta amyloid antibodies
|
CA3071236A1
(en)
|
2017-09-29 |
2019-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
MX2020010092A
(es)
|
2018-03-30 |
2020-10-28 |
Amgen Inc |
Variantes de anticuerpo c-terminales.
|
JP7465814B2
(ja)
*
|
2018-04-16 |
2024-04-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
高濃度タンパク質製剤の粘度低下
|
CN112739323A
(zh)
|
2018-05-10 |
2021-04-30 |
瑞泽恩制药公司 |
含有高浓度vegf受体融合蛋白的制剂
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
IL267923B2
(en)
*
|
2018-08-02 |
2023-06-01 |
Grifols Worldwide Operations Ltd |
The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
|
CA3152838A1
(en)
*
|
2019-08-30 |
2021-03-04 |
Kashiv Biosciences, Llc |
Novel formulation of highly concentrated pharmacologically active antibody
|
EP3808777A1
(en)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stable liquid antibody formulations
|
AU2021308997A1
(en)
|
2020-07-13 |
2023-02-02 |
Merck Patent Gmbh |
Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
|
AR123085A1
(es)
|
2020-07-31 |
2022-10-26 |
Genentech Inc |
FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS
|
WO2023175035A1
(en)
*
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|
DE202024000928U1
(de)
|
2024-05-10 |
2024-05-16 |
Genentech, Inc. |
Omalizumab-Spritze
|